This view has recently gained experimental support with the identification of two compounds that inhibit the activity of the USP1/UAF1 complex, and reverse the resistance of NSCLC cells to cisplatin [94], a DNA damaging drug commonly used in cancer chemotherapy. This evidence concerns the gene USP1 and cancer.